The DuPont Human Microbiome Venture entered a research partnership with Procter & Gamble, focusing on the discovery and development of next-generation probiotics
The DuPont Human Microbiome Venture (Copenhagen, Denmark) entered a research partnership with Procter & Gamble (P&G), focusing on the discovery and development of next-generation probiotics (NPGs) for human health. Although the two companies have conducted extensive research on human commensals, to accelerate the development and commercialization of NGPs, both companies are joining forces to develop NGPs, initially to be used in dietary supplements for metabolic health.
“It’s an exciting opportunity to partner with P&G to jointly develop the next generation of microbe-based products. The combination of DuPont’s and P&G’s unique set of capabilities will allow us to accelerate innovation in the field of metabolic health and help millions of consumers affected by metabolic health issues,” said Sebastien Guery, DuPont's Human Microbiome Venture leader, in a press release.
“As a company focused on innovation, P&G is excited to come together with our valued partners at DuPont,” added Paul Gama, president, P&G Personal Health Care. P&G already manufactures a probiotic called Align, which Gama says is the leading brand recommended by doctors and gastroenterologists to support a healthy digestive system. “This strategic partnership will help us further advance our probiotic innovation via a next generation solution that will prove beneficial to the health and well-being of consumers around the world,” states Gama.